NASDAQ / LIVE COMPANY INTELLIGENCE

Collegium Pharmaceutical, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCOLL
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / COLL COVERAGE

What’s moving Collegium Pharmaceutical, Inc. now

Current reporting with the operating signal separated from the noise.

01
Collegium Pharmaceutical, Inc. (COLL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Collegium Pharmaceutical, Inc. (COLL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

The story matters when it changes Collegium Pharmaceutical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Collegium Pharmaceutical, Inc. (COLL) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript

Collegium Pharmaceutical, Inc. (COLL) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript

The story matters when it changes Collegium Pharmaceutical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Collegium Pharmaceutical, Inc. to Present at Mizuho Neuro & Ophthalmology Summit and Jefferies Global Healthcare Conference

Collegium Pharmaceutical, Inc. to Present at Mizuho Neuro & Ophthalmology Summit and Jefferies Global Healthcare Conference

The story matters when it changes Collegium Pharmaceutical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Collegium Pharmaceutical, Inc. Provides 2025 Financial Guidance with Projected Revenue of Up to $750 Million

Collegium Pharmaceutical, Inc. Provides 2025 Financial Guidance with Projected Revenue of Up to $750 Million

Investors are testing whether Collegium Pharmaceutical, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call Transcript

Investors are testing whether Collegium Pharmaceutical, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest COLL filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-K/AMaterial company eventFiled 2026-06-30 · Period 2026-05-12SEC ↗8-KMaterial company eventFiled 2026-05-15 · Period 2026-05-14SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-07 · Period 2026-05-14SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-31SEC ↗
EARNINGS / QUARTERLY TRACKER

Collegium Pharmaceutical, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.